Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Add'l Indications Recommended for Valtrex, Glivec
February 5, 2007
- MEXT to Strengthen Anticancer Efforts in FY2007
February 5, 2007
- Pfizer Japan, Astellas Announce Approval of Celecox
February 5, 2007
- Saiseikai Group to Initiate Study in Preparation for Joint Purchasing
February 5, 2007
- New Industry Vision to Focus on Environment for Drug Discovery: EAD Director
February 5, 2007
- MEDICAL DEVICE NEWS IN BRIEF
February 5, 2007
- Global Companies Move toClose Research Lab in Japan
February 5, 2007
- GE Healthcare Bio-Sciences Announces Tie-up with Effector Cell Institute
February 5, 2007
- Astellas, Kirin Tie Up for Fully Human Monoclonal Antibody
February 5, 2007
- Drug Evaluation Forum Begins -Drug Makers, PMDA, Academics to Exchange Opinions-
January 29, 2007
- Korosho to Announce Results of Survey on Use of Generics
January 29, 2007
- Chuikyo Approves NHI Price Listing for Alimta, Doxil
January 29, 2007
- Sysmex Develops in Vitro Diagnostic Technology for Cancers
January 29, 2007
- REGULATORY NEWS IN BRIEF
January 29, 2007
- Korosho Proposes "Medical Device MR System"
January 29, 2007
- Development of Amlodipine + Atorvastatin Combination Underway in Japan: Pfizer
January 29, 2007
- MEDICAL DEVICE NEWS IN BRIEF
January 29, 2007
- Ankhs Develops Drugs for Metastatic Cancer Using NR Ligands
January 29, 2007
- Retirement of Baby Boomers to Change Structure of Social Security System: Mr Kawasaki
January 29, 2007
- Kissei Announces Positive Results from PIII Trials of Silodosin in the US
January 29, 2007
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…